ClinicalTrials.gg
CompletedNCT07160049PERNEUSUpdated Jun 10, 2026

Wearable Focused Ultrasound Stimulation for Peripheral Nerve Pain Management

An interventional study of Cold Pressor Task - Upper Limb and Algometry Pain Tests in the Upper Limb in Pain Management and Peripheral Neuropathic Pain, sponsored by Evan (Huiliang) Wang. Completed at 1 site in United States. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Evan (Huiliang) Wang · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
20 Years to 40 Years
Sex
All
01

Study summary

This study will evaluate the feasibility of a novel wearable focused ultrasound (FUS) device for peripheral nerve stimulation in healthy volunteers. The aim is to assess device operability, usability, tolerability, and physiological responses during standardized sensory tests. Each participant will complete nine \~1-hour study sessions across multiple days, including cold pressor and algometry tasks performed under baseline, sham, and active FUS conditions.

Read the detailed description

This feasibility study will evaluate a wearable focused ultrasound (FUS) system designed for non-invasive peripheral nerve stimulation of upper and lower extremity nerves. The primary objective is to determine device feasibility - operability, tolerability, usability, and physiological responses - during standardized pain sensitivity tasks.

Each participant will complete nine sessions on separate days (\~1 hour each) in a within-subject crossover design:

  1. Cold pressor test (baseline, sham, active FUS) - 3 days
  2. Upper limb algometry (baseline, sham, active FUS) - 3 days
  3. Lower limb algometry (baseline, sham, active FUS) - 3 days

Sessions will be scheduled at least 24 hours apart to avoid carryover effects. Approximately 12-15 participants will be enrolled. Although feasibility studies often include fewer than 10 participants, this sample size was chosen to ensure variability across limb anatomy and usability testing. No efficacy hypotheses or clinical outcomes will be tested.

02

Conditions studied

  • Pain Management
  • Peripheral Neuropathic Pain

Keywords

  • Focused Ultrasound
  • Peripheral Nerve Stimulation
  • Wearable Neurotechnology
  • Non-Invasive Neuromodulation
  • Pain Threshold
  • Pain Modulation
  • Radial Nerve
  • Tibial Nerve
  • Saphenous Nerve
  • Experimental Pain Testing
  • Ultrasound Neuromodulation
03

In context

Lead sponsor

Evan (Huiliang) Wang is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Healthy adults aged 20-40, willing and able to undergo FUS experiments.

Exclusion criteria

Exclusion Criteria:

  • Major physical illnesses.
  • Diagnosis of a cognitive disorder.
  • Cardiovascular conditions (e.g., high blood pressure, heart disease, or dysrhythmia), history of fainting or seizures, or history of frostbite.
  • Open cuts, sores, or bone fractures on the limb to be immersed in water, or a history of Raynaud's phenomenon.
  • Diagnosis of or hyposensitivity to bodily sensations (temperature, vibrotactile, nociception).
  • Inability to provide for FUS stimulation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Active Focused Ultrasound (FUS) Stimulation

    Participants will receive active focused ultrasound stimulation applied to peripheral nerves (radial, median, ulnar, tibial, saphenous, or peroneal) using a wearable FUS device. Stimulation will be performed during pain sensitivity assessments, including cold pressor tests and pressure algometry, to record pain perception/thresholds as exploratory physiological responses during feasibility testing.

    Device: Cold Pressor Task - Upper Limb · Device: Algometry Pain Tests in the Upper Limb · Device: Algometry Pain Tests in the Lower Limb

  • Sham comparator
    Sham Focused Ultrasound (FUS) Stimulation

    Participants will undergo the same procedures as the experimental arm (device placement, cold pressor test, and pressure algometry) but with the FUS device set to sham (no active ultrasound output). This arm is used to control for placebo and non-specific effects of device application during pain sensitivity assessments.

    Device: Cold Pressor Task - Upper Limb · Device: Algometry Pain Tests in the Upper Limb · Device: Algometry Pain Tests in the Lower Limb

Interventions

  • DeviceCold Pressor Task - Upper Limb

    This study uses a three-session cold pressor paradigm to evaluate feasibility of a wearable focused ultrasound (FUS) device for peripheral nerve stimulation. Session 1 (Baseline): After consent, participants immerse the dominant hand in 0-1 °C water (\~10 cm depth) in an insulated bucket. Time to first pain is recorded, with 5 min rests between immersions (12 total; max single immersion 6 min). Water temperature is digitally monitored, with ice added as needed. Session 2 (Sham): The median/ulnar/radial nerve in the dominant forearm is located by ultrasound. The FUS device is applied with hydrogel but set to sham (no output). The cold pressor protocol is repeated. Session 3 (Active FUS): After nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The cold pressor test is repeated to record pain tolerance as an exploratory physiological response during feasibility testing.

  • DeviceAlgometry Pain Tests in the Upper Limb

    This session records pressure pain thresholds in the dominant hand with a wearable FUS device and a pressure algometer during feasibility testing. Session 1 (Baseline): After consent and briefing, the median, ulnar, and radial nerves at three points on the dominant hand (wrist, palm, finger) are located via ultrasound and marked. A pressure algometer is applied to each site, with pressure gradually increased until pain is first reported. Thresholds are recorded, with each location tested three times with short breaks. Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated. Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing.

  • DeviceAlgometry Pain Tests in the Lower Limb

    This session records pressure pain thresholds in the dominant foot with a wearable FUS device and a pressure algometer during feasibility testing. Session 1 (Baseline): After consent and briefing, the tibial, saphenous, and peroneal nerves at three standardized points on the dominant foot are located via ultrasound and marked. A pressure algometer is applied to each site, and pressure is gradually increased until pain is first reported. Thresholds are recorded, with repeated trials and short breaks between tests. Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated. Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is then repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing.

06

What researchers measure

Primary outcomes

  1. Completion Rate of Study Sessions

    Proportion of participants who complete all nine planned sessions (baseline, sham, active FUS for cold pressor, upper limb algometry, and lower limb algometry) without withdrawal or device malfunction.

    Time frame: Through study completion (9 study visits over approximately 3 weeks).

Secondary outcomes

  1. Cold Pressor Pain Onset Time

    Time (seconds) from immersion of the hand in ice water until pain is first reported; measured during baseline, sham, and active FUS sessions to characterize physiological response during feasibility testing (not powered for efficacy).

    Time frame: 3 separate study visits (~1 hour each) over approximately 1 week.

  2. Upper Limb Algometry Pain Threshold

    Maximum tolerated pressure (kgf) at standardized points on the hand and forearm before pain is reported, measured using a pressure algometer during baseline, sham, and active FUS sessions. Recorded as an exploratory physiological response during feasibility testing.

    Time frame: 3 separate study visits (~1 hour each) over approximately 1 week.

  3. Lower Limb Algometry Pain Threshold

    Maximum tolerated pressure (kgf) at standardized points on the foot before pain is reported, measured using a pressure algometer during baseline, sham, and active FUS sessions. Recorded as an exploratory physiological response during feasibility testing.

    Time frame: 3 separate study visits (~1 hour each) over approximately 1 week.

07

Study locations

1 site
  • Biomedical Enginering Building - UT Austin
    Austin, Texas 78705, United States
08

References and documents

Publications

  • Legon W, Rowlands A, Opitz A, Sato TF, Tyler WJ. Pulsed ultrasound differentially stimulates somatosensory circuits in humans as indicated by EEG and FMRI. PLoS One. 2012;7(12):e51177. doi: 10.1371/journal.pone.0051177. Epub 2012 Dec 4. PubMed 23226567 ↗
  • Dickey TC, Tych R, Kliot M, Loeser JD, Pederson K, Mourad PD. Intense focused ultrasound can reliably induce sensations in human test subjects in a manner correlated with the density of their mechanoreceptors. Ultrasound Med Biol. 2012 Jan;38(1):85-90. doi: 10.1016/j.ultrasmedbio.2011.09.020. Epub 2011 Nov 21. PubMed 22104527 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Sep 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Sep 8, 2025
StartActual
Jul 14, 2025
Primary completionActual
Sep 15, 2025
CompletionActual
Oct 15, 2025
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07160049
Lead sponsor
Evan (Huiliang) Wang
Responsible party
Evan (Huiliang) Wang (Assistant Professor, University of Texas at Austin) — Sponsor-investigator
First posted
Sep 8, 2025
Start date
Jul 14, 2025
Primary completion
Sep 15, 2025
Completion
Oct 15, 2025
Last update
Jun 10, 2026

Study contacts

Huiliang Wang, PhD
principal investigator · University of Texas at Austin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion